Edwards Lifesciences Corporation $EW Shares Sold by Wendell David Associates Inc.

Key Points

• Wendell David Associates Inc. reduced its holdings in Edwards Lifesciences by 40.7%, selling 7,275 shares and leaving them with a total of 10,620 shares valued at approximately $831,000.
• Several analysts have upgraded their price targets for Edwards Lifesciences, with Wells Fargo raising theirs from $84.00 to $88.00, reflecting strong investor confidence in the stock.
• Insider sales were reported, notably by Larry L. Wood, who sold 8,950 shares at an average price of $78.06, which decreased his position by 4.15%.

Wendell David Associates Inc. lowered its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 40.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,620 shares of the medical research company's stock after selling 7,275 shares during the quarter. Wendell David Associates Inc.'s holdings in Edwards Lifesciences were worth $831,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Quantbot Technologies LP purchased a new position in Edwards Lifesciences during the first quarter worth approximately $26,000. SouthState Corp purchased a new position in Edwards Lifesciences during the first quarter worth approximately $27,000. Rosenberg Matthew Hamilton purchased a new position in Edwards Lifesciences during the second quarter worth approximately $28,000. Tradewinds Capital Management LLC raised its stake in Edwards Lifesciences by 102.5% during the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after purchasing an additional 205 shares during the period. Finally, Rossby Financial LCC purchased a new position in Edwards Lifesciences during the first quarter worth approximately $29,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

EW has been the topic of a number of recent analyst reports. Wells Fargo & Company increased their price target on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a research note on Thursday, August 7th. Stifel Nicolaus set a $85.00 target price on shares of Edwards Lifesciences and gave the company a "buy" rating in a research note on Monday, September 22nd. Deutsche Bank Aktiengesellschaft raised their target price on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, July 25th. The Goldman Sachs Group reissued a "buy" rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Finally, Argus raised shares of Edwards Lifesciences to a "strong-buy" rating in a research note on Thursday, July 10th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of "Moderate Buy" and an average target price of $87.06.

Insider Activity

In other news, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company's stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Price Performance

EW opened at $74.50 on Friday. The company has a fifty day simple moving average of $77.54 and a 200 day simple moving average of $76.19. The firm has a market cap of $43.74 billion, a price-to-earnings ratio of 10.72, a PEG ratio of 3.58 and a beta of 1.05. Edwards Lifesciences Corporation has a twelve month low of $64.89 and a twelve month high of $83.00. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business's revenue was up 11.9% on a year-over-year basis. During the same period last year, the business earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.